Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16281706 | 0.86 | PREP (0.54) | HTTABCB1LMNASMN1; SMN2TGM2 | |
| SCHEMBL3426821 | 0.86 | PREP (0.54) | HTTABCB1LMNASMN1; SMN2TGM2 | |
| SCHEMBL13032648 | 0.86 | PREP (0.54) | HTTABCB1LMNASMN1; SMN2TGM2 | |
| SCHEMBL3578965 | 0.84 | POLB (0.55) | SMN1; SMN2POLBPREP | |
| SCHEMBL8660402 | 0.84 | POLB (0.55) | SMN1; SMN2POLBPREP | |
| SCHEMBL14012812 | 0.84 | POLB (0.55) | SMN1; SMN2POLBPREP | |
| SCHEMBL8697857 | 0.84 | POLB (0.55) | SMN1; SMN2POLBPREP | |
| SCHEMBL9586427 | 0.84 | POLB (0.55) | SMN1; SMN2POLBPREP | |
| SCHEMBL12164616 | 0.84 | POLB (0.55) | SMN1; SMN2POLBPREP | |
| SCHEMBL13032587 | 0.83 | GAA (0.52) | HTTLMNASMN1; SMN2TGM2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | HTT 1374/4885ABCB1 2830/4885LMNA 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.